Clinical Trials Logo

Carcinoma, Squamous Cell clinical trials

View clinical trials related to Carcinoma, Squamous Cell.

Filter by:

NCT ID: NCT04369937 Recruiting - Clinical trials for Head and Neck Squamous Cell Carcinoma

HPV-16 Vaccination and Pembrolizumab Plus Cisplatin for "Intermediate Risk" HPV-16-associated Head and Neck Squamous Cell Carcinoma

Start date: July 6, 2020
Phase: Phase 2
Study type: Interventional

This clinical trial will evaluate a new combination of pembrolizumab, HPV-16 E6/E7 specific therapeutic vaccination (ISA101b) and cisplatin-based chemoradiotherapy for patients with newly diagnosed, local-regionally advanced, intermediate risk HPV-associated head and neck squamous cell carcinoma.

NCT ID: NCT04367909 Recruiting - Clinical trials for Oral Squamous Cell Carcinoma

A Study of TC(Docetaxel and Carboplatin) Regimen With or Without Nimotuzumab in Recurrent Metastatic Oral Squamous Cell Carcinoma

Start date: June 21, 2020
Phase: Phase 2
Study type: Interventional

This prospective, single-center, randomized, controlled study will evaluate the efficacy and safety of TC Regimenwith or without nimotuzumab in recurrent metastatic oral squamous cell carcinoma. Treatment may continue as long as participants are experiencing clinical benefit as assessed by the investigator, i.e., in the absence of unacceptable toxicity or symptomatic deterioration attributed to disease progression.

NCT ID: NCT04359199 Recruiting - Clinical trials for Head and Neck Cancer

QUantitative Assessment of Swallowing After Radiation (QUASAR)

QUASAR
Start date: September 1, 2020
Phase:
Study type: Observational

To use novel methods for quantitative analysis of VFSS (videofluoroscopic swallow study, also known as modified barium swallow) to study and compare dysphagia in patients treated for head and neck carcinoma with concurrent radiation therapy and chemotherapy (cisplatin) or targeted therapy (cetuximab) vs. immunotherapy (pembrolizumab, nivolumab, or durvalumab). Our hypothesis is that pharyngeal constriction will be greater (lower ratio) with concurrent immunotherapy compared to chemotherapy, as measured by the pharyngeal constriction ratio (PCR).

NCT ID: NCT04333537 Recruiting - Clinical trials for Oral Cavity Squamous Cell Carcinoma

Comparing Sentinel Lymph Node (SLN) Biopsy With Standard Neck Dissection for Patients With Early-Stage Oral Cavity Cancer

Start date: July 8, 2020
Phase: Phase 2/Phase 3
Study type: Interventional

This phase II/III trial studies how well sentinel lymph node biopsy works and compares sentinel lymph node biopsy surgery to standard neck dissection as part of the treatment for early-stage oral cavity cancer. Sentinel lymph node biopsy surgery is a procedure that removes a smaller number of lymph nodes from your neck because it uses an imaging agent to see which lymph nodes are most likely to have cancer. Standard neck dissection, such as elective neck dissection, removes many of the lymph nodes in your neck. Using sentinel lymph node biopsy surgery may work better in treating patients with early-stage oral cavity cancer compared to standard elective neck dissection.

NCT ID: NCT04328948 Recruiting - Clinical trials for Esophageal Squamous Cell Carcinoma

A Randomized Controlled Trial Evaluating of Prophylactic Irradiation in CRT for cT1bN0M0 ESCC

ARMADILLO
Start date: July 1, 2020
Phase: Phase 3
Study type: Interventional

This study is conducted to investigate whether modified chemoradiotherapy with elective nodal irradiation reduces the locoregional recurrence that cannot be completely resected by salvage endoscopic resection and preserve esophagus without compromising overall survival.

NCT ID: NCT04315701 Recruiting - Clinical trials for Recurrent Skin Squamous Cell Carcinoma

A PD-1 Checkpoint Inhibitor (Cemiplimab) for High-Risk Localized, Locally Recurrent, or Regionally Advanced Skin Cancer

Start date: June 17, 2020
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well cemiplimab before surgery works in treating patients with skin cancer that is high-risk and has not spread to other parts of the body (localized), has come back locally (locally recurrent), or has spread regionally (regionally advanced), and can be removed by surgery (resectable). Immunotherapy with monoclonal antibodies, such as cemiplimab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.

NCT ID: NCT04290546 Recruiting - Clinical trials for Squamous Cell Carcinoma of the Head and Neck

CIML NK Cell in Head & Neck Cancer

Start date: July 20, 2020
Phase: Phase 1
Study type: Interventional

This research study is evaluating the safety and efficacy of a combination drug and biologic therapy in patients with advanced head and neck cancer. This research study involves the following drugs and biologics: - CIML NK donor cells - IL-15 superagonist - Ipilimumab - Cetuximab

NCT ID: NCT04284540 Recruiting - Clinical trials for Head and Neck Squamous Cell Carcinoma (HNSCC)

Hypofractionated Radiotherapy in Elderly Patients With Head & Neck Squamous Cell Carcinoma

Start date: July 1, 2019
Phase: N/A
Study type: Interventional

The purpose of this research study is to investigate a shorter radiation treatment schedule for head and neck cancers in patients 70 years of age and older. Standard radiation treatment for head and neck patients normally requires that the patient travel to the hospital daily for 6-7 weeks to receive radiation treatment 5 days per week. This long course of radiation can lead to significant side effects resulting in some people being unable to complete the course of treatment. If this happens, and there are gaps in the radiation treatment, this can lead to worse outcomes.

NCT ID: NCT04278989 Recruiting - Clinical trials for Squamous Cell Cancer of the Oral Cavity

Inhibition of Oral Tumorigenesis by Antitumor B

Start date: April 22, 2022
Phase: Early Phase 1
Study type: Interventional

This is a window of opportunity study of Anti-tumor B (ATB). Anti-tumor B is a botanical agent composed of six Chinese herbs: Sophora tonkinensis, Polygonum bistorta, Prunella vulgaris, Sonchus brachyotus, Dictamnus dasycarpus, and Dioscorea bulbifera.

NCT ID: NCT04275986 Recruiting - Clinical trials for Esophageal Squamous Cell Carcinoma

Concurrent Chemoradiotherapy After Endoscopic Resection for Stage I Esophageal Carcinoma

Start date: January 20, 2020
Phase: Phase 2
Study type: Interventional

This is a prospective single-arm study of endoscopic resection (ER) following concurrent chemoradiotherapy for stage I esophageal squamous cell carcinoma, to find if the treatment combination is useful by assessing its safety and efficacy.